Ascletis Pharma Inc. has announced the commencement of a U.S. 13-week Phase IIa study involving participants with obesity or overweight, who have been dosed with the small molecule oral GLP-1 receptor agonist, ASC30. This investigational drug, designed for once-daily oral or once-monthly subcutaneous administration, demonstrated a placebo-adjusted mean body weight reduction of up to 6.5% from baseline after four weeks in a previous Phase Ib study. Topline data from the current Phase IIa study are expected to be presented in the fourth quarter of 2025. ASC30 is a new chemical entity with patent protection in the U.S. and globally until 2044.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on July 03, 2025, and is solely responsible for the information contained therein.